Injectable Long-Acting Cabotegravir-Rilpivirine Therapy for People Living With HIV/AIDS: Addressing Implementation Barriers From the Start.
Injectable Long-Acting Cabotegravir-Rilpivirine Therapy for People Living With HIV/AIDS: Addressing Implementation Barriers From the Start.
复制标题
DOI：
10.1097/jnc.0000000000000386
复制
发表时间：
2023-03-01
影响因子：
2
通讯作者：
Tomlin, Ryan
中科院分区：
文献类型：
--
作者：
Pinto, Rogerio M.;Hall, Evan;Tomlin, Ryan
由医疗提供者每两个月给药一次的注射用卡替拉韦和利匹韦林（CAB/RPV）方便，并改善了隐私和药物管理。批准一年后，无数的实施障碍威胁着这项拯救生命的创新的可获得性和可持续性：（1）资格问题（病毒抑制，耐药性和口服方案失败）;（2）注射需要医疗提供者和运输到设施;（3）严格的药物依从性;（4）生活挑战-心理健康，无家可归，失业;以及（5）缺乏保险和高成本。CAB/RPV的普遍实施要求社会、人类和卫生组织合作，提供艾滋病毒连续护理和预防服务，以促进CAB/RPV的获得和维护，并要求透明的健康保险计费做法，以减少CAB/RPV分类为药物或医疗福利的不确定性以及相关的成本影响。
Injectable cabotegravir and rilpivirine (CAB/RPV), administered bimonthly by a medical provider, is convenient and improves privacy and medication management. One year after approval, myriad implementation barriers threaten the access and sustainability of this life-saving innovation: (1) eligibility issues (viral suppression, drug resistance, and failed oral regimens); (2) injection requires medical provider and transportation to facility; (3) strict medication adherence; (4) life challenges—mental health, homelessness, joblessness; and (5) lack of insurance and high cost. Universal implementation of CAB/RPV calls for social, human, and health organizations to partner and provide HIV continuum of care and prevention services to facilitate CAB/RPV access and maintenance and for transparent health insurance billing practices to abate uncertainty concerning CAB/RPV's classification as a pharmaceutical or medical benefit and related cost implications.
影响因子：
--
作者：
De Vito A;Botta A;Berruti M;Castelli V;Lai V;Cassol C;Lanari A;Stella G;Shallvari A;Bezenchek A;Di Biagio A
通讯作者：
Di Biagio A